

ORIGINAL ARTICLE | VOLUME 145, ISSUE 2, P239-248.E5, FEBRUARY 2008

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1

Carl D. Regillo • David M. Brown • Prema Abraham • ... Susan Schneider • Naveed Shams
The PIER Study Group • Show all authors

Published: December 03, 2007 • DOI: <https://doi.org/10.1016/j.ajo.2007.10.004>

Purchase Subscribe Save Share Reprints Request

PlumX Metrics

- References
- Biography
- Article info
- Related Articles

Purpose

To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Design

Phase IIIb, multicenter, randomized, double-masked, sham injection-controlled trial in patients with predominantly or minimally classic or occult with no classic CNV lesions.

Methods

Patients were randomized 1:1:1 to 0.3 mg ranibizumab (n = 60), 0.5 mg ranibizumab (n = 61), or sham (n = 63) treatment groups. The primary efficacy endpoint was mean change from baseline visual acuity (VA) at month 12.

Results

Mean changes from baseline VA at 12 months were -16.3, -1.6, and -0.2 letters for the sham, 0.3 mg, and 0.5 mg groups, respectively (P ≤ .0001, each ranibizumab dose vs sham). Ranibizumab arrested CNV growth and reduced leakage from CNV. However, the treatment effect declined in the ranibizumab groups during quarterly dosing (e.g., at three months the mean changes from baseline VA had been gains of 2.9 and 4.3 letters for the 0.3 mg and 0.5 mg doses, respectively). Results of subgroups analyses of mean change from baseline VA at 12 months by baseline age, VA, and lesion characteristics were consistent with the overall results. Few serious ocular or nonocular adverse events occurred in any group.

Conclusions

Ranibizumab administered monthly for three months and then quarterly provided significant VA benefit to patients with AMD-related subfoveal CNV and was well tolerated. The incidence of serious ocular or nonocular adverse events was low.

To read this article in full you will need to make a payment

Purchase one-time access:

Academic & Personal: 24 hour online access

Corporate R&D Professionals: 24 hour online access

► One-time access price info

Subscribe:

Subscribe to American Journal of Ophthalmology

Already a print subscriber? [Claim online access](#)

Already an online subscriber? [Sign in](#)

Register: [Create an account](#)

Institutional Access: [Sign in to ScienceDirect](#)

References

- Rosenfeld P.J. • Brown D.M. • Heier J.S. • et al. **Ranibizumab for neovascular age-related macular degeneration.** *N Engl J Med.* 2006; 355: 1419-1431
[View in Article](#) [Scopus \(4740\)](#) [PubMed](#) [Crossref](#) [Google Scholar](#)

2. Brown D.M. • Kaiser P.K. • Michels M. • et al.
Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
N Engl J Med. 2006; **355**: 1432-1444
[View in Article](#) ^
[Scopus \(2982\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
3. Heier J.S. • Antoszyk A.N. • Pavan P.R. • et al.
Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study.
Ophthalmology. 2006; **113**: 633-642
[View in Article](#) ^
[Scopus \(353\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
4. Rosenfeld P.J. • Heier J.S. • Hantsbarger G. • Shams N.
Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Ophthalmology. 2006; **113**: 623-632
[View in Article](#) ^
[Scopus \(168\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
5. Hochberg Y.
A sharper Bonferroni procedure for multiple tests of significance.
Biometrika. 1988; **75**: 800-802
[View in Article](#) ^
[Scopus \(3737\)](#) • [Crossref](#) • [Google Scholar](#)
6. **Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of two randomized clinical trials—TAP report 1.**
Arch Ophthalmol. 1999; **117**: 1329-1345
[View in Article](#) ^
[Scopus \(1738\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
7. **Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin.**
Ophthalmology. 2001; **108**: 841-852
[View in Article](#) ^
[Scopus \(462\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)
8. Visudyne. Novartis Pharmaceuticals Corp, East Hanover, New Jersey 2005 ((package insert))
[View in Article](#) ^
[Google Scholar](#)
9. **Collaborative overview of randomized trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.**
BMJ. 1994; **308**: 81-106
[View in Article](#) ^
[Scopus \(708\)](#) • [PubMed](#) • [Crossref](#) • [Google Scholar](#)
10. Fung A.E. • Lalwani G.A. • Rosenfeld P.J. • et al.
An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Am J Ophthalmol. 2007; **143**: 566-583
[View in Article](#) ^
[Scopus \(868\)](#) • [PubMed](#) • [Abstract](#) • [Full Text](#) • [Full Text PDF](#) • [Google Scholar](#)

Biography



Carl D. Regillo received his medical degree from Harvard and performed both his ophthalmology residency and vitreoretinal fellowship at Wills Eye Institute, Philadelphia, Pennsylvania. He is a prior Heed fellow and recipient of the American Academy of Ophthalmology Achievement and Senior Achievement Awards. Dr Regillo is currently the Director of the Wills Clinical Retina Research Unit, Professor of Ophthalmology at Thomas Jefferson University, and Chairman of the Academy Retina section of the Basic and Clinical Science Course.

Article info

Publication history

Published online: December 03, 2007
Accepted: October 5, 2007

Footnotes

Supplemental Material available at AJO.com.

Identification

DOI: <https://doi.org/10.1016/j.ajo.2007.10.004>

Copyright

© 2008 Elsevier Inc. Published by Elsevier Inc. All rights reserved.

ScienceDirect

[Access this article on ScienceDirect](#)

Related Articles

- Home
- AI/Deep Learning
- Cataracts
- Cornea and External Disease
- COVID-19
- Epidemiology
- Glaucoma
- International/Preventative
- Neuro-Ophthalmology
- Oculoplastics
- Pediatrics
- Refractive Surgery
- Research
- Retina
- Uveitis
- ARTICLES AND ISSUES
- Current Issue
- Internet Advance
- List of Issues
- COLLECTIONS
- American Ophthalmological Society Theses
- Centennial
- Editorship Series
- Edward Jackson Memorial Lectures
- Series on Epidemiology
- Series on Statistics
- Subject Collections
- Supplemental Material
- CME
- CME Information and Guidelines for Manuscript Review
- Therapeutic Strategies for the Treatment of Ocular Surface Disorders
- FOR AUTHORS
- About Open Access
- Author Information
- Researcher Academy
- Submit Your Manuscript
- JOURNAL INFO
- About the Journal
- About Open Access
- Abstracting/Indexing
- Career Opportunities
- Contact Information
- Editorial Board
- Info for Advertisers
- Pricing
- Reviewers
- New Content Alerts
- SUBSCRIBE
- MORE PERIODICALS
- Find a Periodical
- Go to Product Catalog
- ALERTS
- How to subscribe to a subject collection
- How to create a saved search

We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the [Cookie settings | Your Privacy Choices](#) for this site.

